Targeting tumors with LIGHT to generate metastasis-clearing immunity
1Section of Dermatology, Department of Medicine, University of Chicago, MC5067 Chicago, IL 60637, USA. pingyu@uchicago.edu
Cytokine & Growth Factor Reviews
|May 30, 2008
Summary
Tumor necrosis factor superfamily member 14 (TNFSF14) LIGHT can overcome tumor barriers to enhance anti-tumor immunity. Intratumor LIGHT therapy shows promise for treating various cancers without needing specific tumor antigens.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Metastatic diseases are a major cause of cancer mortality.
- Tumors create physical and immunological barriers hindering immune responses.
- Current immunotherapies have limited efficacy due to these barriers and antigen dependency.
Purpose of the Study:
- To review the potential of TNFSF14 LIGHT as a novel cancer immunotherapy.
- To highlight LIGHT's role in breaking down tumor barriers and enhancing anti-tumor immunity.
Main Methods:
- Review of recent findings on LIGHT's interactions within the tumor microenvironment.
- Analysis of LIGHT's dual receptor (HVEM and LTbetaR) mediated effects.
- Focus on intratumor administration strategies.
Main Results:
- LIGHT interacts with various immune and tumor cells within tumors.
- Targeting tumors with LIGHT enhances effector cell priming, recruitment, and retention.
- Intratumor LIGHT therapy can inhibit primary tumor growth and eradicate metastases.
Conclusions:
- LIGHT effectively breaks down tumor barriers, enabling potent anti-tumor immunity.
- LIGHT-based immunotherapy offers a promising approach against diverse tumors, independent of specific tumor antigens.
- LIGHT represents a significant candidate for developing effective cancer immunotherapies.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...